Date: 2016-04-18
Type of information: Initiation of the trial
phase: 2
Announcement: initiation of the trial
Company: AstraZeneca (UK) University of Birmingham (UK)
Product: AZD2014 (vistusertib)
Action
mechanism: mTOR inhibitor. Vistusertib is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR, a serine/threonine kinase that is upregulated in a variety of tumors, plays an important role downstream in the PI3K/Akt/mTOR signaling pathway.
Disease: diffuse large B-cell mymphoma
Therapeutic area: Cancer - Oncology
Country: UK
Trial
details: The aim of this clinical trial is to see if AZD2014 (vistusertib) is effective and safe to use to treat patients with relapsed or refractory Diffuse Large BCell Lymphoma (DLBCL). The study will also look at combining rituximab with AZD2014 in a small number of patients to see if this can be done without increasing the toxicity. 36 patients will be recruited to the trial. 30 will receive AZD2014 alone and the remaining 6 will receive AZD2014 plus rituximab. AZD2014 will be given as a 125mg tablet that is to be taken twice a day for 2 days out of every 7 (i.e. on days 1 and 2 of every week). Rituximab will be given via IV infusion on day 1 of every 28 days (once every 4 weeks) for a maximum of 6 cycles. (NCT02752204)
Latest
news: * On April 18, 2016, a Phase 2 trial sponsored by the University of Birmingham was published on the NIH website ClinicalTrials.gov for AZD2014 (vistusertib) and is currently recruiting participants. ("An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (TORCH)")
